OTC · Health care

Accustem Sciences Inc. (ACUT)

It posted a net loss of $1.7M. At June 30, 2026 it held $12.9K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch ACUT in 60 seconds

Price

$0.12

0.00% on the day · September 25, 2026

52-week range $0.12 to $1.69

Market cap

$1.9M

What Accustem Sciences Inc. does

Accustem Sciences Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ACUT.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$1.8M	-$1.8M	-$0.12	n/a
2024	n/a	-$1.5M	-$1.5M	-$0.13	n/a
2023	n/a	-$2.1M	-$2.1M	-$0.18	n/a
2022	n/a	-$3.7M	-$3.7M	-$0.34	-$1.8M
2022	n/a	-$670.6K	-$670.6K	-$0.07	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 11, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 12, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Accustem Sciences Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 14, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue was $98.4K; diluted EPS -$0.02 versus -$0.02.
May 15, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.03 versus -$0.03.
April 14, 2026
Annual report 10-K · period to December 31, 2025Diluted EPS -$0.12 versus -$0.13.
March 31, 2026
Late annual report notice NT 10-K
November 26, 2025
Other event 8-K
November 12, 2025
Quarterly report 10-Q · period to September 30, 2025Diluted EPS -$0.02 versus -$0.03.
August 14, 2025
Quarterly report 10-Q · period to June 30, 2025Diluted EPS was -$0.02.
May 20, 2025
Quarterly report 10-Q · period to March 31, 2025Diluted EPS was -$0.03.
May 15, 2025
Late quarterly report notice NT 10-Q
April 3, 2025
Annual report 10-K · period to December 31, 2024Diluted EPS -$0.13 versus -$0.18.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 16, 2025. Insider transactions on SEC

All filings on SEC EDGAR

Questions about ACUT

What does Accustem Sciences Inc. do?

Accustem Sciences Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker ACUT.

Is Accustem Sciences Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $1.7M.

When did Accustem Sciences Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare ACUT with

Compare ACUT with any company

Follow ACUT

Get an email when Accustem Sciences Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ACUT: get an email when it files

Where the numbers come from

Financial figures are the values Accustem Sciences Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.